Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$2.32 -24.2%	$2.12	$1.11 ▼ $17.88	$59.63M	1.62	750,606 shs	1.61 million shs
DRRX DURECT	$0.63 -1.8%	$0.62	$0.48 ▼ $1.74	$20.01M	0.59	57,507 shs	15,451 shs
ELVN Enliven Therapeutics	$21.50 +1.6%	$19.03	$13.30 ▼ $30.03	$1.04B	0.79	294,544 shs	485,100 shs
EYEN Eyenovia	$9.55 +5.9%	$2.39	$0.85 ▼ $124.80	$26M	1	1.18 million shs	9.36 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	+15.15%	+14.93%	+52.76%	+63.44%	-50.49%
DRRX DURECT	+3.95%	+1.40%	+18.47%	-20.04%	-56.74%
ELVN Enliven Therapeutics	+4.29%	-2.94%	+29.02%	+2.82%	-3.11%
EYEN Eyenovia	+64.60%	+29.41%	+409.60%	+615.87%	-83.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANVS Annovis Bio	2.3716 of 5 stars	3.5	1.0	0.0	3.2	1.7	0.6
DRRX DURECT	0.6007 of 5 stars	0.0	3.0	4.4	0.6	0.0	0.0
ELVN Enliven Therapeutics	2.6581 of 5 stars	3.5	1.0	0.0	3.0	4.2	0.0
EYEN Eyenovia	0.4844 of 5 stars	1.0	2.0	0.0	2.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	3.00	Buy	$30.25	1,203.88% Upside
DRRX DURECT	2.00	Hold	N/A	N/A
ELVN Enliven Therapeutics	3.00	Buy	$39.60	84.19% Upside
EYEN Eyenovia	2.00	Hold	$2.00	-79.06% Downside

Current Analyst Ratings Breakdown

Latest DRRX, EYEN, ANVS, and ELVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/15/2025	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $17.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
3/27/2025	DRRX DURECT	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.67 per share	N/A
DRRX DURECT	$2.03M	9.68	N/A	N/A	$0.29 per share	2.18
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
EYEN Eyenovia	$60K	458.40	N/A	N/A	($695.52) per share	-0.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$24.59M	-$2.16	N/A	N/A	N/A	N/A	-300.56%	-193.50%	8/13/2025 (Estimated)
DRRX DURECT	-$8.32M	-$0.15	N/A	N/A	N/A	-91.54%	-267.36%	-64.00%	8/12/2025 (Estimated)
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
EYEN Eyenovia	-$49.82M	-$58.40	N/A	N/A	N/A	-62,238.41%	-1,108.24%	-316.90%	8/11/2025 (Estimated)

Latest DRRX, EYEN, ANVS, and ELVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/19/2025	Q1 2025	EYEN Eyenovia	-$7.20	-$1.59	+$5.61	-$1.59	$1.60 million	$1.60 million
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/13/2025	Q1 2025	ANVS Annovis Bio	-$0.47	-$0.32	+$0.15	-$0.32	N/A	N/A
3/26/2025	Q4 2024	DRRX DURECT	$0.06	-$0.06	-$0.12	$0.24	$6.91 million	$2.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
DRRX DURECT	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
EYEN Eyenovia	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	10.68	10.68
DRRX DURECT	N/A	1.23	1.22
ELVN Enliven Therapeutics	N/A	21.07	21.06
EYEN Eyenovia	0.58	0.34	0.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
DRRX DURECT	28.03%
ELVN Enliven Therapeutics	95.08%
EYEN Eyenovia	25.84%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	20.80%
DRRX DURECT	3.20%
ELVN Enliven Therapeutics	25.90%
EYEN Eyenovia	7.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
DRRX DURECT	80	31.04 million	30.05 million	Optionable
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
EYEN Eyenovia	40	2.88 million	2.68 million	Optionable

DRRX, EYEN, ANVS, and ELVN Headlines

Recent News About These Companies

Eyenovia Announces Co-Branded Validator with Kinetiq

3 hours ago | tmcnet.com

Eyenovia, Inc. Acquires $50 Million in HYPE Tokens, Plans Validator Deployment and FDA Registration for Optejet UFD - Nasdaq

June 25 at 6:54 AM | nasdaq.com

Eyenovia Climbs After-Hours On Revealing $50M Crypto Play And Validator Node Plans

June 24 at 3:41 AM | msn.com

Eyenovia Closes $50M Private Placement for HYPE Treasury

June 23 at 12:38 PM | coingape.comC

Eyenovia, Inc. Acquires $50 Million in HYPE Tokens, Plans Validator Deployment and FDA Registration for Optejet UFD

June 23 at 8:59 AM | quiverquant.comQ

HYPE Price Drops 20% as Hyperliquid Treasury Announcement Fails to Gather Momentum

June 19, 2025 | coinspeaker.com

Crypto Prices Today: Bitcoin Price Slips Below $106K as XRP Dips 3.25%

June 19, 2025 | analyticsinsight.netA

HYPE Price Drops Below $40 Despite $50M Eyenovia Investment

June 18, 2025 | thecurrencyanalytics.comT

Hyperliquid price outlook amid Eyenovia’s $50M HYPE treasury strategy

June 18, 2025 | coinjournal.net

Nasdaq’s Eyenovia Bets on Hyperliquid, Becomes First Public U.S. Firm to Hold HYPE Tokens

June 18, 2025 | blockonomi.com

Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings

June 18, 2025 | prnewswire.com

Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group

June 18, 2025 | globenewswire.com

Cryptocurrencies Price Prediction: Hyperliquid, Bitcoin & Ethereum — Asian Wrap 18 June

June 18, 2025 | fxstreet.com

Just-In: Nasdaq-Listed Firm Announces Hyperliquid Reserve

June 17, 2025 | coingape.comC

Eyenovia Surges on Crypto Announcement

June 17, 2025 | marketwatch.com

Eyenovia, Inc. Announces $50 Million Private Placement to Acquire HYPE Token and Appoints Hyunsu Jung as Chief Investment Officer

June 17, 2025 | quiverquant.comQ

Eyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy

June 17, 2025 | globenewswire.com

Eyenovia Advances Merger Talks With Betaliq And Targets FDA Filing For Optejet Device

May 22, 2025 | nasdaq.com

Eyenovia provides update on potential merger and Optejet development

May 20, 2025 | msn.com

Eyenovia Reports Q1 2025 Progress and Financials

May 19, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRRX, EYEN, ANVS, and ELVN Company Descriptions

Annovis Bio NYSE:ANVS

$2.32 -0.74 (-24.18%)

Closing price 03:59 PM Eastern

Extended Trading

$2.31 -0.01 (-0.47%)

As of 07:56 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

DURECT NASDAQ:DRRX

$0.63 -0.01 (-1.78%)

As of 04:00 PM Eastern

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Enliven Therapeutics NASDAQ:ELVN

$21.50 +0.34 (+1.61%)

Closing price 04:00 PM Eastern

Extended Trading

$21.51 +0.01 (+0.05%)

As of 04:08 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Eyenovia NASDAQ:EYEN

$9.55 +0.53 (+5.88%)

Closing price 04:00 PM Eastern

Extended Trading

$9.47 -0.08 (-0.80%)

As of 07:59 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time